Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.
Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity.
215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW)
Avonex approval application
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
Cuprizone neurotoxicity in the rat: morphologic observations.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Autoantibodies and pain.
Rituximab does not reset defective early B cell tolerance checkpoints.
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Firategrast
“Human Medicines” page
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
Delta-9-tetrahydrocannabinol/cannabidiol (sativex(®)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.

Pages